Aberdeen Group’s Axcelis ACLS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-32,510
Closed -$2.29M 942
2024
Q4
$2.29M Sell
32,510
-817
-2% -$67.8K ﹤0.01% 749
2024
Q3
$3.5M Sell
33,327
-121,945
-79% -$14.3M 0.01% 707
2024
Q2
$22.1M Buy
155,272
+10,329
+7% +$1.19M 0.04% 359
2024
Q1
$16.2M Sell
144,943
-35,232
-20% -$4.2M 0.03% 455
2023
Q4
$23.4M Buy
180,175
+44,855
+33% +$6.18M 0.05% 352
2023
Q3
$22.1M Buy
135,320
+48,409
+56% +$8.51M 0.06% 309
2023
Q2
$15.9M Buy
+86,911
New +$12.5M 0.04% 385

Other funds holding ACLS

Aberdeen Group's ACLS Position: Q1 2025 in Review

Aberdeen Group sold out of Axcelis (ACLS) in Q1 2025, closing a stake of 32,510 shares — an estimated $2.29M sold.

Aberdeen Group first reported a position in ACLS in Q2 2023 and held it in 7 quarters. The position peaked at $23.4M in Q4 2023. 306 funds tracked by Wall St. Rank hold ACLS as of Q1 2025.

  • Aberdeen Group reported no remaining Axcelis position as of Q1 2025 after selling out during the quarter.
  • Aberdeen Group sold 32,510 Axcelis shares in Q1 2025, an estimated $2.29M.
  • Aberdeen Group first reported a position in Axcelis in Q2 2023 and held it in 7 quarters.
  • Aberdeen Group's Axcelis position peaked at $23.4M in Q4 2023.
  • 306 funds tracked by Wall St. Rank held Axcelis as of Q1 2025.

Based on Aberdeen Group's 13F filing for Q1 2025, filed 13 May 2025.